Table 1 Patient characteristics
Characteristics | Patients |
|---|---|
Entered | n = 97 |
Median age (years) (range) | 46 (25-73) |
Age > 65 years | 12 (12.4%) |
Age < 35 years | 8 (8.2%) |
Stage 4 at primary diagnosis | 24 (24.7%) |
Grade 3 tumour | 64 (66%) |
Invasive ductal carcinoma | 81 (83.5%) |
Positive hormone receptor status | 41 (42.3%) |
Visceral metastases | 73 (75.3%) |
Median metastatic sites (sites) (range) | 2 (1-6) |
   Lung | 36 |
   Liver | 49 |
   Bones | 51 |
   Lymph nodes | 37 |
   Soft tissue | 48 |
   Skin | 16 |
   Brain (before trastuzumab) | 1 |
   Others | 3 |
More than one metastatic site | 78 (80.4%) |
Adjuvant chemotherapy | 67 (69.1%) |
   Anthracyycline based | 37 |
   Taxane based | 2 |
   Combination anthracyclines/taxanes | 22 |
Adjuvant endocrine therapy | 26 (26.8%) |
Adjuvant trastuzumab | 9 (9.3%) |
Duration adjuvant trastuzumab (median) (range) | 10 (4-24) |
Palliative treatment other than trastuzumab-based | 35 (36.1%) |
Second-line combination | Â |
   Taxanes | 21 |
   Vinorelbine | 30 |
   Capecitabine | 23 |
   Gemcitabine | 12 |
   Anthracyclines | 5 |
   Others | 6 |
Trastuzumab beyond second-line | 55 (56.7%) |
Lapatinib beyond second-line trastuzumab | 14 (14.4%) |